Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Haematologica Année : 2007

Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease

Résumé

Delayed hemolytic transfusion reaction (DHTR), a life-threatening transfusion complication in sickle cell disease (SCD), is characterized by a marked hemoglobin drop with destruction of both transfused and autologous red blood cells (RBCs) and exacerbation of SCD symptoms. One mechanism of RBCs destruction is auto-antibody production secondary to transfusion. As rituximab specifically targets circulating B cells, we thought that it could be beneficial in preventing this immune-mediated transfusion complication. We report the case of a SCD patient who previously experienced DHTR with auto-antibodies and who needed a new transfusion. DHTR recurrence was successfully prevented by rituximab administration prior transfusion, supporting the safe use of rituximab to prevent DHTR in SCD patients as a second line approach when other measures failed.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-03241610 , version 1 (28-05-2021)

Identifiants

Citer

F. Noizat-Pirenne, D. Bachir, P. Chadebech, M. Michel, A. Plonquet, et al.. Rituximab for prevention of delayed hemolytic transfusion reaction in sickle cell disease. Haematologica, 2007, 92 (12), pp.e132-e135. ⟨10.3324/haematol.12074⟩. ⟨inserm-03241610⟩
36 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More